1. Home
  2. GLU vs ALDX Comparison

GLU vs ALDX Comparison

Compare GLU & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

HOLD

Current Price

$19.25

Market Cap

119.8M

Sector

Finance

ML Signal

HOLD

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$1.55

Market Cap

101.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLU
ALDX
Founded
2004
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.8M
101.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
GLU
ALDX
Price
$19.25
$1.55
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.50
AVG Volume (30 Days)
9.3K
891.7K
Earning Date
01-01-0001
05-01-2026
Dividend Yield
8.60%
N/A
EPS Growth
N/A
40.43
EPS
0.62
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.53
$1.07
52 Week High
$21.69
$6.18

Technical Indicators

Market Signals
Indicator
GLU
ALDX
Relative Strength Index (RSI) 45.38 36.50
Support Level $19.20 $1.48
Resistance Level $20.17 $1.88
Average True Range (ATR) 0.28 0.09
MACD -0.05 0.02
Stochastic Oscillator 36.61 12.68

Price Performance

Historical Comparison
GLU
ALDX

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: